Solo-Dex is a leading brand revolutionizing regional anesthesia with their innovative Fascile Continuous Peripheral Nerve Block (cPNB) products. Born out of a vision by founding anesthesiologists Drs. Sundar Rajendran and Dan Kopacz, Solo-Dex aimed to create a regional anesthesia solution that is fast, reliable, and easy to use.

Their patented over-the-needle catheter designs provide precise, sustainable, and regulatable acute pain management, setting a new standard of care. With the introduction of Solo-Dex products, the need for post-surgical opioid therapy has been greatly diminished. Patients now have an alternative approach for managing acute pain during recovery without the risks associated with oral opioids.

Additionally, Solo-Dex technology has proved invaluable during the Covid-19 pandemic, reducing airway manipulation in the surgical suite and shortening recovery duration. Under the leadership of MedTech innovator Steve Eror as CEO, Solo-Dex has expanded its reach globally. Their proprietary products are available in the US, European Union, India, Brazil, and the Middle East.

Solo-Dex's mission is to assist patients and healthcare providers in avoiding the risks of general anesthesia, reducing hospital recovery time and discomfort, accelerating hospital discharge, and minimizing the use of opioids during home recovery. Embracing their technology leads to reduced clinical costs for hospitals, increased patient satisfaction, and limited exposure to infections for surgical staff. Contact Solo-Dex for more information about their revolutionary Fascile Continuous Nerve Block Products (cPNB) and take a step towards a safer and more efficient approach to regional anesthesia